Fujioka S, Sasakawa O, Kishimoto H, Tsumura K, Morii H
Second Department of Internal Medicine, Osaka City University Medical School, Japan.
J Hypertens. 1991 Feb;9(2):175-9. doi: 10.1097/00004872-199102000-00013.
To investigate the role of calcitonin gene-related peptide (CGRP) in blood pressure regulation, we used rats with hypertension, induced by the chronic infusion of norepinephrine or angiotensin II, and examined changes in the systemic hemodynamics using the radioactive microspheres method. CGRP (0.05 micrograms/kg per min) administered simultaneously with norepinephrine (1.8 mg/kg per day) significantly reduced the systolic blood pressure of conscious rats compared with norepinephrine infusion alone. Similarly CGRP given with angiotensin II (0.9 mg/kg per day) significantly reduced the systolic blood pressure compared with angiotensin II alone. The antihypertensive effect of CGRP was sustained for 6 days. CGRP infusion decreased the total peripheral resistance but caused no change in cardiac output compared with rats given only pressor substances. Thus, a subdepressor dose of CGRP can modulate the vasopressor effects of norepinephrine and angiotensin II. CGRP may be involved in the regulation of blood pressure via an effect on peripheral vascular resistance.
为研究降钙素基因相关肽（CGRP）在血压调节中的作用，我们使用了通过慢性输注去甲肾上腺素或血管紧张素II诱导高血压的大鼠，并采用放射性微球法检测全身血流动力学变化。与单独输注去甲肾上腺素相比，同时给予CGRP（0.05微克/千克每分钟）和去甲肾上腺素（1.8毫克/千克每天）可显著降低清醒大鼠的收缩压。同样，与单独给予血管紧张素II相比，给予CGRP和血管紧张素II（0.9毫克/千克每天）可显著降低收缩压。CGRP的降压作用持续了6天。与仅给予升压物质的大鼠相比，输注CGRP可降低总外周阻力，但心输出量无变化。因此，亚降压剂量的CGRP可调节去甲肾上腺素和血管紧张素II的升压作用。CGRP可能通过对外周血管阻力的影响参与血压调节。
